Aptevo Therapeutics Inc. Net Income Loss

• Aptevo Therapeutics Inc. showed a decrease of -7.6% in Net Income Loss from 2024 to 2025.
• This data is from Aptevo Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 11 years of available data (2015 to 2025), Aptevo Therapeutics Inc.'s Net Income Loss has grown by 56.2%.
• Historical annual values: Fiscal year 2025: -$25.97 million | Fiscal year 2024: -$24.13 million | Fiscal year 2023: -$17.41 million | Fiscal year 2022: $8.03 million | Fiscal year 2021: -$28.46 million | Fiscal year 2020: -$17.75 million | Fiscal year 2019: -$40.45 million | Fiscal year 2018: -$53.69 million | Fiscal year 2017: $6.97 million | Fiscal year 2016: -$112.42 million | Fiscal year 2015: -$59.32 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026